Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise MoveThe Motley Fool • 03/17/26
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 03/17/26
Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash salesMarket Watch • 03/17/26
Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares24/7 Wall Street • 03/17/26
Why One Analyst Thinks LLY Is Worth $850 While the Rest of Wall Street Targets $1,21624/7 Wall Street • 03/17/26
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitisPRNewsWire • 03/16/26
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12Benzinga • 03/12/26
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs?Zacks Investment Research • 03/12/26